Concepedia

Sevan Habeshian

SH

Statistics

Publications

15

Citations

718

H-Index

12

Active since

2011

Affiliations

École Polytechnique Fédérale de Lausanne(Current)

AMAG Pharmaceuticals (United States)

Novartis (Switzerland)

AstraZeneca (United States)

AstraZeneca (Sweden)

Sevan Habeshian is an author at École Polytechnique Fédérale de Lausanne specializing in drug discovery, pharmacy, and drug design.

ORCID

Publications per year

2011–2024

15

Publications

15

De novo development of small cyclic peptides that are orally bioavailable

Manuel L. Merz, Sevan Habeshian, Bo Li et al. · Nature Chemical Biology · 2023 · 120 citations · Full text

, , +16

Encoded Library Synthesis Using Chemical Ligation and the Discovery of sEH Inhibitors from a 334-Million Member Library

Alexander Litovchick, Christoph E. Dumelin, Sevan Habeshian et al. · Scientific Reports · 2015 · 108 citations · Full text

, , +17

Discovery of a Potent BTK Inhibitor with a Novel Binding Mode by Using Parallel Selections with a DNA‐Encoded Chemical Library

John W. Cuozzo, Diana Gikunju, Sevan Habeshian et al. · ChemBioChem · 2017 · 80 citations · Full text

, , +17

Multivalent Glycocluster Design through Directed Evolution

Iain Macpherson, J. Sebastian Temme, Sevan Habeshian et al. · Angewandte Chemie International Edition · 2011 · 76 citations · Full text

, , +15

Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors

Jeffrey W. Johannes, Stephanie M. Bates, Carl Beigie et al. · ACS Medicinal Chemistry Letters · 2016 · 60 citations · Full text

, , +17

1–5 of 15